Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247387 · ClinicalTrials.gov registry record
eOnOff - D1 Extension
A clinical trial, sponsored by Boston University.
- Completed
- Registry status
- 34
- Enrollment target
NCT03247387: Completed study, sponsored by Boston University.
NCT03247387 is a clinical trial that has completed, run by Boston University. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03247387 has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
Clinical assessments can only offer a snapshot of daily life with Parkinson's Disease, while wearable devices can offer immensely more information that can improve the understanding of this disease. With recent advancements in technology, investigators are now able to use watch-like devices to more effectively measure the symptoms of Parkinson's Disease outside of the doctor's office. The present study is designed to evaluate the usability, applicability, and interpretability of an electronic VA Patient Motor Diary (eON-OFF), MC10 BioStampRC actigraphy sensor, APDM actigraphy sensor and the GENEActiv Watch in persons with Parkinson's Disease. There is no placebo/control group.
Primary Outcome
Subjects will use the eON-OFF motor diary application to select their current Parkinson state (e.g. "on", "off"). Subjects will also use the eON-OFF motor diary application to verbally record symptomology every 30 minutes while awake.
Interventions
- DEVICE MC10 BioStampRC
- DEVICE APDM actigraphy device
- DEVICE GENEActiv watch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2019-01-22 |
What the finished NCT03247387 record still lists
NCT03247387 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which MC10 BioStampRC is the first listed.
NCT03247387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03247387 about?
NCT03247387 is a clinical study titled "eOnOff - D1 Extension". Clinical assessments can only offer a snapshot of daily life with Parkinson's Disease, while wearable devices can offer immensely more information that can improve the understanding of this disease. With recent advancements in technology, investigators are now able to use watch-like devices to more ...
What is the current status of trial NCT03247387?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2017-05-02. Estimated completion is 2019-01-22.
What interventions are being tested in trial NCT03247387?
The interventions under investigation include: MC10 BioStampRC (DEVICE), APDM actigraphy device (DEVICE), GENEActiv watch (DEVICE).
Who is sponsoring clinical trial NCT03247387?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI